X Fu1,2, X Pang1, H Qi1, S Chen1, Y Li1, W Tan3. 1. Department of Urology, Nanfang Hospital, Southern Medical University, No. 1838, North of Guangzhou Avenue, Baiyun District, Guangzhou, 510515, Guangdong Province, China. 2. Department of Urology, Kaiping Central Hospital, Kaiping, 529300, China. 3. Department of Urology, Nanfang Hospital, Southern Medical University, No. 1838, North of Guangzhou Avenue, Baiyun District, Guangzhou, 510515, Guangdong Province, China. drtanwl@163.com.
Abstract
BACKGROUND: Bladder cancer is the second most common urological malignancy around the world and is by far the most frequent urological malignancy in China. Embelin is an active compound identified as a novel X-chromosome-linked IAP (XIAP) inhibitor from the Embelia ribes that exhibits various medicinal effects including anti-inflammatory and anti-cancer activities. However, therapeutic effect of Embelin to human bladder cancer is not yet determined. METHODS: We evaluated the sensitizing potential of Embelin on inhibiting cell growth and migration of bladder cancer cell line by CCK8, Transwell, and Western Blot, and explored its related mechanism. We performed IHC staining of XIAP in 35 bladder cancer tissues and corresponding adjacent non-neoplastic tissues. RESULTS: XIAP was significantly upregulated in bladder cancer cases. When the concentration of Embelin was used respectively at 5, 10, 20, 25, and 35 µmol/l, the survival of both T24 and 5637 cells decreased in a dose-/time-dependent manner. Our study confirmed that with the increase of concentration of Embelin, the expression levels of PI3K and p-Akt decreased significantly which further confirmed that Embelin inhibits cell growth by inducing apoptosis via PI3K/Akt pathway. CONCLUSIONS: Embelin may be developed into a novel and potential chemotherapeutic drug for bladder cancer.
BACKGROUND:Bladder cancer is the second most common urological malignancy around the world and is by far the most frequent urological malignancy in China. Embelin is an active compound identified as a novel X-chromosome-linked IAP (XIAP) inhibitor from the Embelia ribes that exhibits various medicinal effects including anti-inflammatory and anti-cancer activities. However, therapeutic effect of Embelin to humanbladder cancer is not yet determined. METHODS: We evaluated the sensitizing potential of Embelin on inhibiting cell growth and migration of bladder cancer cell line by CCK8, Transwell, and Western Blot, and explored its related mechanism. We performed IHC staining of XIAP in 35 bladder cancer tissues and corresponding adjacent non-neoplastic tissues. RESULTS:XIAP was significantly upregulated in bladder cancer cases. When the concentration of Embelin was used respectively at 5, 10, 20, 25, and 35 µmol/l, the survival of both T24 and 5637 cells decreased in a dose-/time-dependent manner. Our study confirmed that with the increase of concentration of Embelin, the expression levels of PI3K and p-Akt decreased significantly which further confirmed that Embelin inhibits cell growth by inducing apoptosis via PI3K/Akt pathway. CONCLUSIONS: Embelin may be developed into a novel and potential chemotherapeutic drug for bladder cancer.
Authors: J Alfred Witjes; Eva Compérat; Nigel C Cowan; Maria De Santis; Georgios Gakis; Thierry Lebret; Maria J Ribal; Antoine G Van der Heijden; Amir Sherif Journal: Eur Urol Date: 2013-12-12 Impact factor: 20.096
Authors: Amy V Paschall; Mary A Zimmerman; Christina M Torres; Dafeng Yang; May R Chen; Xia Li; Erhard Bieberich; Aiping Bai; Jacek Bielawski; Alicja Bielawska; Kebin Liu Journal: BMC Cancer Date: 2014-01-15 Impact factor: 4.430